United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News InhaleRx (ASX: IRX) unveils oral esketamine therapy for depression but stock sinks 22% amid investor caution InhaleRx launches SRX-25 oral esketamine therapy for depression, plans rebrand and raises capital despite 22% stock plunge. Learn what this could mean for investors. byVenkateshNovember 26, 2025